Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 27 peer-reviewed journal articles Updated
Hematology

How Are Low Platelets and Bleeding Treated in Myelofibrosis?

At a Glance

Low platelets and bleeding in myelofibrosis are treated according to the platelet count, bleeding symptoms, medicines, and overall health. Care may include adjusting myelofibrosis therapy, platelet transfusions, clotting tests, and emergency treatment for serious bleeding.

In this answer

5 sections

01

Understanding Why You Are Bleeding

02

Adjusting Your Myelofibrosis Treatment

03

Supportive Care and Platelet Transfusions

04

Medications: What to Avoid and Manage Carefully

05

When to Contact Your Team vs. Seek Emergency Care

Low platelets (thrombocytopenia) and bleeding in myelofibrosis are managed through a combination of approaches: selecting treatments that are safe for your platelet levels, adjusting other medications, and using supportive care like platelet transfusions.

In medical terms, platelet counts are often written as numbers like 50 × 10⁹/L, which equals 50,000 platelets per microliter (µL). A count below 50 × 10⁹/L (50,000/µL) is considered severe thrombocytopenia [1] [2]. However, your personal bleeding risk isn’t determined by this number alone—your doctor will also look at your bleeding history, medications, and overall health to create an individualized plan for you.

Understanding Why You Are Bleeding

In myelofibrosis, your platelet count can drop because scar tissue in the bone marrow impairs blood cell production, or because an enlarged spleen traps and destroys platelets [3].

However, some patients experience severe bleeding even when their platelet count is normal. This can happen for several reasons, including as examples:

  • Acquired von Willebrand syndrome (aVWS): A condition where the proteins that help platelets stick together are depleted or don’t function correctly [4] [5].
  • Platelet dysfunction: The platelets themselves are misshapen or fail to work properly [6] [7].
  • Other factors: Liver disease, other medical conditions, or medications like blood thinners.

If you are bleeding, your doctor may check your coagulation (clotting) factors and von Willebrand tests, even if your platelet count is normal [4]. Treatment might involve treating the myelofibrosis itself or using specialized medications rather than a platelet transfusion.

Adjusting Your Myelofibrosis Treatment

Your platelet level heavily influences which targeted therapies (JAK inhibitors) are safest for you:

  • Ruxolitinib and Fedratinib: These medications can lower platelet counts further, so they are generally avoided or used with extreme caution if you have severe thrombocytopenia [8] [9].
  • Pacritinib: This is specifically approved for patients with myelofibrosis whose platelets are below 50 × 10⁹/L (50,000/µL) [10]. While studies show it can improve spleen size and symptoms in this group [11], serious bleeding is still a recognized risk in myelofibrosis, and you will need close monitoring.
  • Momelotinib: This therapy is particularly relevant if you have severe myelofibrosis-associated anemia, and may be an option depending on your specific platelet levels and your doctor’s assessment [8] [12].

Supportive Care and Platelet Transfusions

If you have active, significant bleeding, you may receive a platelet transfusion [13]. Transfusions are also used preventatively before invasive procedures. Goals are individualized by your medical team, but examples from guidelines include raising platelets above 50 × 10⁹/L for major surgery, or above 20 × 10⁹/L for a lumbar puncture (spinal tap) [14].

Keep in mind that an enlarged spleen or a fever can rapidly consume transfused platelets, making the transfusion short-lived [15]. If your platelet count repeatedly fails to increase after transfusions (a condition called refractoriness), your team will investigate the cause [16]. If the cause is immune-related (antibodies destroying the platelets), they may use specialized matched (HLA-selected) platelets for future transfusions [17].

Medications: What to Avoid and Manage Carefully

Never stop or change a prescribed blood thinner or daily aspirin without talking to the doctor who prescribed it. Doing so abruptly can cause dangerous blood clots.

  • Aspirin and NSAIDs: Over-the-counter nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen or naproxen interfere with platelet function and increase bleeding risk [18] [19]. Always ask your care team before taking any new over-the-counter pain relievers or supplements.
  • Blood Thinners (Anticoagulants): Blood thinners increase bleeding risk. For example, one registry study of intermediate and high-risk myelofibrosis patients found that those on blood thinners had a nearly sevenfold higher rate of major bleeding [20]. However, myelofibrosis still carries a risk of life-threatening blood clots even when platelets are low [21]. Your doctor will carefully balance these risks, which may involve reducing the dose or pausing the blood thinner depending on how low your platelets drop [22].

When to Contact Your Team vs. Seek Emergency Care

Call your hematology team the same day if you notice:

  • New or spreading petechiae (tiny red/purple dots on the skin).
  • Recurrent nosebleeds or increasing bruising.
  • Minor bleeding that is new or unusual for you.

Seek IMMEDIATE emergency medical care (Call 911 or go to the ER) for:

  • Bleeding that won’t stop after applying firm, direct pressure. (Apply firm, continuous direct pressure to any external bleeding while you get help.)
  • Black, tarry stools, vomiting blood, or coughing up blood [23] [24].
  • Blood in your urine, or heavy, unusual vaginal bleeding.
  • A sudden, severe headache, extreme confusion, or fainting (potential signs of bleeding in the brain) [25] [26].
  • A suddenly painful, swollen, tense, and pale arm or leg (could indicate a clot or internal bleeding) [27].
  • Any major head injury, especially if you take a blood thinner.

Common questions in this guide

What treatments are used for low platelets in myelofibrosis?
Treatment is individualized based on your platelet count, bleeding symptoms, medicines, and overall health. It may include adjusting myelofibrosis therapy, using a treatment suited to very low platelets, and giving platelet transfusions for significant bleeding or before a procedure.
Can myelofibrosis cause bleeding even when my platelet count is normal?
Yes. Problems with the proteins that help platelets stick together, abnormal platelet function, liver disease, and medicines such as blood thinners can cause bleeding even when the platelet number is normal. Your doctor may order clotting-factor and von Willebrand tests to find the cause.
Is pacritinib an option when my platelets are below 50,000?
Pacritinib is specifically approved for people with myelofibrosis whose platelet counts are below 50 × 10⁹/L, or 50,000 per microliter. It may improve spleen size and symptoms, but serious bleeding remains possible, so close monitoring is needed.
When should bleeding with myelofibrosis be treated as an emergency?
Get emergency care for bleeding that does not stop with firm pressure, black stools, vomiting or coughing blood, blood in the urine, heavy unusual vaginal bleeding, or a sudden severe headache, confusion, or fainting. A major head injury is also urgent, especially if you take a blood thinner.
Should I stop aspirin or a blood thinner if my platelets fall?
No. Do not stop or change a prescribed blood thinner or daily aspirin without speaking with the clinician who prescribed it, because myelofibrosis can still cause dangerous clots. Your care team may adjust the dose or pause it after weighing your bleeding and clotting risks.
Why might a platelet transfusion not raise my count for long?
An enlarged spleen or fever can quickly remove or use transfused platelets, so the benefit may be short-lived. If counts repeatedly fail to rise, your team may investigate platelet-transfusion refractoriness and consider specially matched platelets when antibodies are involved.

Related questions

How Do Doctors Choose a JAK Inhibitor for Myelofibrosis? Is Myelofibrosis Hereditary? Should Relatives Be Tested? Can My Myelofibrosis Risk Score Change Over Time? Does Prefibrotic Myelofibrosis Need Treatment or Monitoring? How to Manage Fullness and Weight Loss in Myelofibrosis?
Show more
How Common Is Myelofibrosis and Who Is at Risk? Explained How Is Accelerated or Blast-Phase Myelofibrosis Diagnosed? How Is Myelofibrosis-Related Anemia Treated? Key Options How Is Post-PV/ET Myelofibrosis Different From Primary MF? How Often Are Myelofibrosis Monitoring Visits Needed? What Are My Treatment Options if a JAK Inhibitor Fails? Positive JAK2, CALR or MPL Post-Transplant: What Now? What Does Triple-Negative Myelofibrosis Mean for Your Care? What Do White Blood Cell Counts Mean in Myelofibrosis? Can I Exercise Safely With Myelofibrosis and Splenomegaly? What Happens During a Bone Marrow Biopsy for Myelofibrosis? What If I Need Frequent Transfusions for Myelofibrosis? What Blood Tests Are Needed for JAK Inhibitors in Myelofibrosis? When Should Myelofibrosis Tests Be Repeated After Changes?

Get notified when new evidence is published on myelofibrosis.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (27)
  1. 1

    Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.

    Masarova L, Alhuraiji A, Bose P, et al.

    European journal of haematology 2018; (100(3)):257-263 doi:10.1111/ejh.13005.

    PMID: 29226426
  2. 2

    [A study of clinical characteristics and prognosis of primary myelofibrosis patients with thrombocytopenia in varied degrees].

    Xu ZF, Qin TJ, Zhang HL, et al.

    Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi 2019; (40(1)):12-16 doi:10.3760/cma.j.issn.0253-2727.2019.01.003.

    PMID: 30704222
  3. 3

    Thrombocytopenia in Patients With Myelofibrosis: A Practical Management Guide.

    Tremblay D, Baine I, Mascarenhas J

    Clinical lymphoma, myeloma & leukemia 2022; (22(12)):e1067-e1074 doi:10.1016/j.clml.2022.08.011.

    PMID: 36117043
  4. 4

    Acquired von Willebrand Syndrome During the Course of Myelofibrosis: Analysis of 32 Cases.

    Mital A, Prejzner W, Hellmann A

    Advances in clinical and experimental medicine : official organ Wroclaw Medical University 2015; (24(6)):1001-6 doi:10.17219/acem/52361.

    PMID: 26771972
  5. 5

    Acquired von willebrand syndrome in patients with philadelphia-negative myeloproliferative neoplasm.

    Song IC, Kang S, Lee MW, et al.

    Blood research 2023; (58(1)):42-50 doi:10.5045/br.2023.2022218.

    PMID: 36774948
  6. 6

    Severe acquired platelet dysfunction because of primary myelofibrosis with full functional and morphological recovery after allogeneic hematopoietic cell transplantation.

    Linnik YA, Salvatore LT, Lowrey CH, Ornstein DL

    Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 2019; (30(8)):419-422 doi:10.1097/MBC.0000000000000850.

    PMID: 31483321
  7. 7

    Acquired Gray Platelet Syndrome Associated with Primary Myelofibrosis.

    Ido K, Nakane T, Tanizawa N, et al.

    Internal medicine (Tokyo, Japan) 2020; (59(21)):2751-2756 doi:10.2169/internalmedicine.4912-20.

    PMID: 32641652
  8. 8

    New approaches to tackle cytopenic myelofibrosis.

    Reynolds SB, Pettit K

    Hematology. American Society of Hematology. Education Program 2022; (2022(1)):235-244 doi:10.1182/hematology.2022000340.

    PMID: 36485113
  9. 9

    How I individualize selection of JAK inhibitors for patients with myelofibrosis.

    Masarova L, Chifotides HT

    Blood 2025; (145(16)):1724-1737 doi:10.1182/blood.2023022415.

    PMID: 39357058
  10. 10

    Pacritinib for myelofibrosis in adults with thrombocytopenia.

    Yang DH, Lu Q, Zhu Z, et al.

    Drugs of today (Barcelona, Spain : 1998) 2022; (58(12)):577-589 doi:10.1358/dot.2022.58.12.3474538.

    PMID: 36651066
  11. 11

    Retrospective analysis of pacritinib in patients with myelofibrosis and severe thrombocytopenia.

    Verstovsek S, Mesa R, Talpaz M, et al.

    Haematologica 2022; (107(7)):1599-1607 doi:10.3324/haematol.2021.279415.

    PMID: 34551507
  12. 12

    Momelotinib in Myelofibrosis Patients With Thrombocytopenia: Post Hoc Analysis From Three Randomized Phase 3 Trials.

    Kiladjian JJ, Vannucchi AM, Gerds AT, et al.

    HemaSphere 2023; (7(11)):e963 doi:10.1097/HS9.0000000000000963.

    PMID: 37908862
  13. 13

    Thrombocytopenia in the intensive care unit: diagnosis and management.

    Pène F, Russell L, Aubron C

    Annals of intensive care 2025; (15(1)):25 doi:10.1186/s13613-025-01447-x.

    PMID: 39985745
  14. 14

    Platelet Transfusion: 2025 AABB and ICTMG International Clinical Practice Guidelines.

    Metcalf RA, Nahirniak S, Guyatt G, et al.

    JAMA 2025; (334(7)):606-617 doi:10.1001/jama.2025.7529.

    PMID: 40440268
  15. 15

    Non-Alloimmune Mechanisms of Thrombocytopenia and Refractoriness to Platelet Transfusion.

    Belizaire R, Makar RS

    Transfusion medicine reviews 2020; (34(4)):242-249 doi:10.1016/j.tmrv.2020.09.002.

    PMID: 33129606
  16. 16

    Efficacy of cross-match compatible platelets in multi transfused haemato-oncology patients refractory to platelet transfusion.

    Chavan A, Sharma RR, Saikia B, et al.

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2019; (58(6)):102657 doi:10.1016/j.transci.2019.09.010.

    PMID: 31706911
  17. 17

    Diagnosis and Management of Immune Platelet Transfusion Refractoriness.

    Reda S, Rühl H

    Hamostaseologie 2026; doi:10.1055/a-2887-8181.

    PMID: 42331028
  18. 18

    Risk factors for bleeding, including platelet count threshold, in newly diagnosed immune thrombocytopenia adults.

    Piel-Julian ML, Mahévas M, Germain J, et al.

    Journal of thrombosis and haemostasis : JTH 2018; (16(9)):1830-1842 doi:10.1111/jth.14227.

    PMID: 29978544
  19. 19

    Risk Factors for and Management of MPN-Associated Bleeding and Thrombosis.

    Martin K

    Current hematologic malignancy reports 2017; (12(5)):389-396 doi:10.1007/s11899-017-0400-3.

    PMID: 28948496
  20. 20

    Predictors of thrombosis and bleeding in 1613 myelofibrosis patients from the Spanish Registry of Myelofibrosis.

    Hernández-Boluda JC, Pastor-Galán I, Arellano-Rodrigo E, et al.

    British journal of haematology 2022; (199(4)):529-538 doi:10.1111/bjh.18440.

    PMID: 36089912
  21. 21

    Risk-based and individualised management of bleeding and thrombotic events in adults with primary immune thrombocytopenia (ITP).

    Lambert C, Maitland H, Ghanima W

    European journal of haematology 2024; (112(4)):504-515 doi:10.1111/ejh.14154.

    PMID: 38088207
  22. 22

    EHA Guidelines on Management of Antithrombotic Treatments in Thrombocytopenic Patients With Cancer.

    Falanga A, Leader A, Ambaglio C, et al.

    HemaSphere 2022; (6(8)):e750 doi:10.1097/HS9.0000000000000750.

    PMID: 35924068
  23. 23

    Masked polycythemia vera presenting as non-cirrhotic portal hypertension with isolated gastric varices: a case report.

    Jallad H, Khaled A, Qabaja H, et al.

    BMC gastroenterology 2026; (26(1)).

    PMID: 42443774
  24. 24

    Recurrent Upper Gastrointestinal Bleeding from Isolated Gastric Varices as Primary Symptom of Myelofibrosis: A Case Report on Combining Interventional and Pharmacologic Treatment Options.

    Giszas B, Weber M, Heidel FH, Reuken PA

    Digestive diseases (Basel, Switzerland) 2022; (40(4)):530-534 doi:10.1159/000518766.

    PMID: 34348280
  25. 25

    Refractory hemorrhage in chronic subdural hematoma: primary myelofibrosis with subdural extramedullary hematopoiesis. Illustrative case.

    Shomura K, Nakashima Y, Kurose N, et al.

    Journal of neurosurgery. Case lessons 2025; (9(25)).

    PMID: 40550209
  26. 26

    A case of perirenal extramedullary hematopoiesis in a patient with primary myelofibrosis.

    Imai K, Aoi T, Kitai H, et al.

    CEN case reports 2017; (6(2)):194-199 doi:10.1007/s13730-017-0274-1.

    PMID: 28895103
  27. 27

    Use of Recombinant Factor VIIa for Bleeding Control in Treatment of Acute Extremity Compartment Syndrome Secondary to Primary Myelofibrosis: A Case Report.

    Demirel M, Kendirci AŞ, Özmen E, Polat G

    JBJS case connector 2021; (11(3)) doi:10.2106/JBJS.CC.21.00337.

    PMID: 34319921

This page is for informational purposes only and does not constitute medical advice. Your hematology team should guide medication changes, transfusions, and urgent care decisions for your situation.